Literature DB >> 1797818

High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics.

J E Franc1, G F Duncan, R H Farmen, K A Pittman.   

Abstract

A quantitative analytical method, using high-performance liquid chromatography and ultraviolet detection, has been established for the determination of nefazodone (NEF) and its metabolites, m-chlorophenylpiperazine (mCPP),p-hydroxynefazodone (PHN), and hydroxynefazodone (HO-NEF), in human plasma. The fully automated, robotic procedure consisted of addition of internal standard (aprindine), extraction with butyl chloride, followed by phase separation, organic phase evaporation, reconstitution of the residue, and injection onto the chromatographic system. The limits of detection for NEF, mCPP, PHN, and HO-NEF were 5, 1, 10, and 5 ng/ml, respectively, at a signal-to-noise ratio of 4. The method had a linear range of 10-1000 ng/ml for NEF and HO-NEF, 20-2000 ng/ml for PHN, and 2.5-250 ng/ml for mCPP. Correlation coefficients of 0.996 or greater were obtained during validation and study sample analysis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797818     DOI: 10.1016/0378-4347(91)80207-s

Source DB:  PubMed          Journal:  J Chromatogr


  10 in total

Review 1.  Clinical pharmacokinetics of nefazodone.

Authors:  D S Greene; R H Barbhaiya
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

2.  Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment.

Authors:  R H Barbhaiya; U A Shukla; D S Greene
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease.

Authors:  R C Dockens; D Rapoport; D Roberts; D S Greene; R H Barbhaiya
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

Review 4.  Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Authors:  R Davis; R Whittington; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

5.  Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function.

Authors:  R H Barbhaiya; M E Brady; U A Shukla; D S Greene
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 6.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

7.  Pharmacokinetics of nefazodone in the dog following single oral administration.

Authors:  U A Shukla; P H Marathe; J A Labudde; K A Pittman; R H Barbhaiya
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

8.  Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog.

Authors:  U A Shukla; S Kaul; P H Marathe; K A Pittman; R H Barbhaiya
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

9.  Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.

Authors:  P H Marathe; D E Salazar; D S Greene; J Brennan; U A Shukla; R H Barbhaiya
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

10.  Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.

Authors:  R H Barbhaiya; U A Shukla; D S Greene
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.